Patent · US Active

GSK-3β inhibitors and use thereof in methods of treatment

US11254700B2 · kind B2 · utility

0Cited by
0References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 30, 2018
Grant dateFeb 22, 2022
Priority date—
Expiry dateNov 30, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07C49/835
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Isoorientin analogues and related compounds that inhibit glycogen synthase kinase-3β activity are provided as are methods of using these compounds in the treatment of cognitive, neurodegenerative or neurological diseases or conditions, as well as cancer, obesity, diabetes, inflammatory or autoimmune disease, cardiovascular disorder, metabolic syndrome X, hair loss, severe acute respiratory syndrome coronavirus, cocaine addiction, dental caries, bone loss and glaucoma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.